Literature DB >> 372809

Advances in the treatment of acute myelogenous leukemia.

R P Gale.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 372809     DOI: 10.1056/NEJM197905243002105

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  34 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.

Authors:  L M Wang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

Authors:  V I Avramis; R A Mecum; J Nyce; D A Steele; J S Holcenberg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

5.  Aggressive or non-aggressive tumor therapy.

Authors:  P Reizenstein
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

6.  Cytogenetic studies in bone marrow transplant recipients.

Authors:  O A Haas; W Hinterberger; W Schmidmeier; C Pollak; M Hinterberger; H Gadner; K Lechner
Journal:  Blut       Date:  1986-07

7.  Use of the circuit simulation program SPICE2 for analysis of the metabolism of anticancer drugs.

Authors:  J C White
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

8.  Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.

Authors:  A T Look; G V Dahl; G Rivera; A M Mauer
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  [Clinical relevance of glucocorticoid receptors in the treatment of lymphoid neoplasias].

Authors:  U Gehring; A D Ho
Journal:  Klin Wochenschr       Date:  1987-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.